Monroe Carell Jr. Children's Hospital at Vanderbilt
Monroe Carell Jr. Children's Hospital at Vanderbilt
Monroe Carell Jr. Children's Hospital at Vanderbilt
Children's Hospital Logo
Connect With Us:

Monroe Carell Jr.
Children's Hospital
at Vanderbilt
2200 Children's Way
Nashville, TN 37232


(615) 936-1000

Children's Hospital Logo
Printer friendly version of this page  E-mail someone a link to this pageBookmark and Share

Cystic Fibrosis Research

 


Cystic Fibrosis Registry

This multicenter database tracks CF patients. Any patient with CF is eligible to participate.

Twin - Sibling Genetic Modifiers
This national multicenter study seeks other genetic markers that can explain the variations in the clinical picture of CF, and potentially provide new opportunities for modifying therapies. Blood samples and history are collected from eligible patients.

Viral Surveillance in Cystic Fibrosis
The role of viral disease in CF is not known. This Vanderbilt study collects samples from CF patients during clinic visits to determine what viruses are present in CF patients and the best methods for detection. The study is a joint effort with the Division of Allergy, Immunology and Pulmonary Medicine, and the Division of Infectious Disease.

DHA Supplementation
CF patients experience increased inflammation and altered fatty acids. DHA supplements have been used in mouse models and in humans with other inflammatory diseases. This pilot study seeks to determine if DHA supplements alter markers of inflammation in CF.

Biomarkers of Pulmonary Exacerbation
CF patients need frequent antibiotics for pulmonary exacerbations. This study examines blood markers of inflammation to develop improved tests that could determine when patients need antibiotics.

EPIC
Infection with pseudomonas is frequent in CF. This multicenter study follows patients before and after they develop pseudomonas, with blood and culture samples.

VERTEX -102
VX770 is a new medication developed to correct the CF protein. About 5 percent of CF patients have a mutations which potentially respond to the treatment. Vanderbilt is participating in the multicenter studies of this therapy. Patients over age 12 with certain mutations are eligible to participate.

VERTEX -104
During the first studies of VX770 it was discovered it may also help patients with the common CF mutation 508. This multicenter study evaluatinges VX770 in patients with 508/508 mutations.


Last Edited: May 31, 2016
Valued Participant of Vanderbilt Health Affiliated Network